Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
$82.3K
2 trades · 1 insiders
Net · 90d
$-82.3K
Insiders on file
14
Daily buy vs sell · 90 days
■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President, Director | 32 | $0 | $482.6K | 2026-09-08 |
| Lorrain Daniel S. | Chief Scientific Officer | 44 | $0 | $1.25M | 2026-07-09 |
| Watkins Tim | CMO & Head of Development | 16 | $0 | $322.5K | 2026-06-30 |
| Miralles Gines Diego | Director | 3 | $0 | $0 | 2026-06-26 |
| Brady Todd R. | Director | 3 | $0 | $0 | 2026-06-26 |
| Schimmelpennink Evert B. | Director | 3 | $0 | $0 | 2026-06-26 |
| Lyons-Williams Lori | Director | 3 | $0 | $0 | 2026-06-26 |
| Ware Olivia C | Director | 3 | $0 | $0 | 2026-06-26 |
| Boyce Sarah | Director | 3 | $0 | $0 | 2026-06-26 |
| Ignelzi Troy A. | Director | 4 | $0 | $0 | 2026-06-26 |
| Healy John Stephen | General Counsel and Corp Sec | 3 | $0 | $0 | 2026-01-30 |
| Slover Peter T | Chief Financial Officer | 3 | $0 | $0 | 2026-01-30 |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | 4 | $0 | $0 | 2025-01-31 |
| Versant Vantage I, L.P. | 10% Owner | 21 | $0 | $0 | 2024-04-09 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President | M Exercise deriv | 2026-09-08 | 2026-09-08 | 2,500 | — | $0 | 274,430 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise | 2026-09-08 | 2026-09-08 | 2,500 | $1.01 | $2.5K | 19,717 | SEC↗ |
| Stengone Carmine N. | CEO and President | S Sale | 2026-09-08 | 2026-09-08 | 2,500 | $16.46 | $41.1K | 17,217 | SEC↗ |
| Stengone Carmine N. | CEO and President, Director | M Exercise deriv | 2026-09-08 | 2026-09-08 | 2,500 | — | $0 | 274,430 | SEC↗ |
| Stengone Carmine N. | CEO and President, Director | S Sale | 2026-09-08 | 2026-09-08 | 2,500 | $16.46 | $41.1K | 17,217 | SEC↗ |
| Stengone Carmine N. | CEO and President, Director | M Exercise | 2026-09-08 | 2026-09-08 | 2,500 | $1.01 | $2.5K | 19,717 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise deriv | 2026-08-03 | 2026-08-03 | 2,500 | — | $0 | 276,930 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise | 2026-08-03 | 2026-08-03 | 2,500 | $1.01 | $2.5K | 19,717 | SEC↗ |
| Stengone Carmine N. | CEO and President | S Sale | 2026-08-03 | 2026-08-03 | 2,500 | $16.01 | $40.0K | 17,217 | SEC↗ |
| Stengone Carmine N. | CEO and President, Director | M Exercise deriv | 2026-08-03 | 2026-08-03 | 2,500 | — | $0 | 276,930 | SEC↗ |
| Stengone Carmine N. | CEO and President, Director | S Sale | 2026-08-03 | 2026-08-03 | 2,500 | $16.01 | $40.0K | 17,217 | SEC↗ |
| Stengone Carmine N. | CEO and President, Director | M Exercise | 2026-08-03 | 2026-08-03 | 2,500 | $1.01 | $2.5K | 19,717 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise deriv | 2026-07-09 | 2026-07-10 | 25 | — | $0 | 33,257 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise | 2026-07-09 | 2026-07-10 | 25 | $1.01 | $25 | 135,227 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-07-09 | 2026-07-10 | 25 | $16.00 | $400 | 135,202 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise deriv | 2026-07-08 | 2026-07-08 | 2,500 | — | $0 | 279,430 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise deriv | 2026-07-08 | 2026-07-10 | 1,015 | — | $0 | 33,282 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise | 2026-07-08 | 2026-07-08 | 2,500 | $1.01 | $2.5K | 19,717 | SEC↗ |
| Stengone Carmine N. | CEO and President | S Sale | 2026-07-08 | 2026-07-08 | 2,500 | $16.00 | $40.0K | 17,217 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-07-08 | 2026-07-10 | 1,015 | $16.00 | $16.2K | 135,202 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise | 2026-07-08 | 2026-07-10 | 1,015 | $1.01 | $1.0K | 136,217 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise deriv | 2026-07-01 | 2026-07-02 | 4,183 | — | $0 | 34,297 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise | 2026-07-01 | 2026-07-02 | 4,183 | $1.01 | $4.2K | 143,555 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-07-01 | 2026-07-02 | 5,852 | $15.67 | $91.7K | 137,703 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-07-01 | 2026-07-02 | 2,501 | $16.24 | $40.6K | 135,202 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise deriv | 2026-06-30 | 2026-07-01 | 7,500 | — | $0 | 281,930 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise deriv | 2026-06-30 | 2026-07-01 | 2,500 | — | $0 | 118,417 | SEC↗ |
| Watkins Tim | CMO & Head of Development | M Exercise deriv | 2026-06-30 | 2026-07-01 | 10,833 | — | $0 | 238,334 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise deriv | 2026-06-30 | 2026-07-02 | 28,826 | — | $0 | 38,480 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise | 2026-06-30 | 2026-07-01 | 2,500 | $1.26 | $3.1K | 27,217 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise | 2026-06-30 | 2026-07-01 | 7,500 | $1.01 | $7.6K | 24,717 | SEC↗ |
| Stengone Carmine N. | CEO and President | S Sale | 2026-06-30 | 2026-07-01 | 10,000 | $16.01 | $160.1K | 17,217 | SEC↗ |
| Watkins Tim | CMO & Head of Development | S Sale | 2026-06-30 | 2026-07-01 | 10,833 | $16.02 | $173.5K | 8,961 | SEC↗ |
| Watkins Tim | CMO & Head of Development | M Exercise | 2026-06-30 | 2026-07-01 | 10,833 | $4.50 | $48.7K | 19,794 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise | 2026-06-30 | 2026-07-02 | 28,826 | $1.01 | $29.1K | 168,198 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-06-30 | 2026-07-02 | 28,826 | $16.04 | $462.4K | 139,372 | SEC↗ |
| Boyce Sarah | Director | A Award deriv | 2026-06-26 | 2026-06-26 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Brady Todd R. | Director | A Award deriv | 2026-06-26 | 2026-06-26 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Ignelzi Troy A. | Director | A Award deriv | 2026-06-26 | 2026-06-26 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Schimmelpennink Evert B. | Director | A Award deriv | 2026-06-26 | 2026-06-26 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Ware Olivia C | Director | A Award deriv | 2026-06-26 | 2026-06-26 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Lyons-Williams Lori | Director | A Award deriv | 2026-06-26 | 2026-06-26 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Miralles Gines Diego | Director | A Award deriv | 2026-06-26 | 2026-06-26 | 19,000 | — | $0 | 19,000 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-06-01 | 2026-06-01 | 4,170 | $13.16 | $54.9K | 139,372 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-05-01 | 2026-05-01 | 3,870 | $13.06 | $50.5K | 143,842 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-05-01 | 2026-05-01 | 300 | $13.84 | $4.2K | 143,542 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-04-06 | 2026-04-06 | 4,170 | $13.43 | $56.0K | 147,712 | SEC↗ |
| Watkins Tim | CMO & Head of Development | M Exercise deriv | 2026-03-02 | 2026-03-02 | 3,611 | — | $0 | 249,167 | SEC↗ |
| Watkins Tim | CMO & Head of Development | S Sale | 2026-03-02 | 2026-03-02 | 3,611 | $15.02 | $54.2K | 0 | SEC↗ |
| Watkins Tim | CMO & Head of Development | M Exercise | 2026-03-02 | 2026-03-02 | 3,611 | $4.50 | $16.2K | 3,611 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-03-02 | 2026-03-02 | 4,170 | $15.01 | $62.6K | 151,882 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise deriv | 2026-02-25 | 2026-02-26 | 3,824 | — | $0 | 67,306 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise deriv | 2026-02-25 | 2026-02-26 | 2,700 | — | $0 | 120,917 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise | 2026-02-25 | 2026-02-26 | 3,824 | $1.01 | $3.9K | 159,876 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-02-25 | 2026-02-26 | 3,824 | $16.01 | $61.2K | 156,052 | SEC↗ |
| Stengone Carmine N. | CEO and President | S Sale | 2026-02-25 | 2026-02-26 | 2,700 | $16.02 | $43.3K | 14,954 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise | 2026-02-25 | 2026-02-26 | 2,700 | $1.26 | $3.4K | 17,654 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise deriv | 2026-02-24 | 2026-02-26 | 4,300 | — | $0 | 71,130 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise deriv | 2026-02-24 | 2026-02-26 | 4,400 | — | $0 | 123,617 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-02-24 | 2026-02-26 | 4,300 | $16.03 | $68.9K | 156,052 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise | 2026-02-24 | 2026-02-26 | 4,300 | $1.01 | $4.3K | 160,352 | SEC↗ |
| Stengone Carmine N. | CEO and President | S Sale | 2026-02-24 | 2026-02-26 | 4,400 | $16.02 | $70.5K | 14,954 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise | 2026-02-24 | 2026-02-26 | 4,400 | $1.26 | $5.5K | 19,354 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise deriv | 2026-02-19 | 2026-02-20 | 100 | — | $0 | 75,430 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise | 2026-02-19 | 2026-02-20 | 100 | $1.01 | $101 | 156,152 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-02-19 | 2026-02-20 | 100 | $16.00 | $1.6K | 156,052 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise deriv | 2026-02-11 | 2026-02-13 | 400 | — | $0 | 75,530 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise deriv | 2026-02-11 | 2026-02-13 | 400 | — | $0 | 128,017 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-02-11 | 2026-02-13 | 400 | $16.00 | $6.4K | 156,052 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | M Exercise | 2026-02-11 | 2026-02-13 | 400 | $1.01 | $404 | 156,452 | SEC↗ |
| Stengone Carmine N. | CEO and President | S Sale | 2026-02-11 | 2026-02-13 | 400 | $16.00 | $6.4K | 14,954 | SEC↗ |
| Stengone Carmine N. | CEO and President | M Exercise | 2026-02-11 | 2026-02-13 | 400 | $1.26 | $504 | 15,354 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-02-03 | 2026-02-05 | 1,170 | $15.25 | $17.8K | 156,052 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-02-03 | 2026-02-05 | 3,000 | $14.82 | $44.5K | 157,222 | SEC↗ |
| Watkins Tim | CMO & Head of Development | A Award deriv | 2026-01-30 | 2026-01-30 | 160,000 | — | $0 | 160,000 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | A Award deriv | 2026-01-30 | 2026-01-30 | 6,500 | — | $0 | 6,500 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | A Award deriv | 2026-01-30 | 2026-01-30 | 160,000 | — | $0 | 160,000 | SEC↗ |
| Stengone Carmine N. | CEO and President | A Award deriv | 2026-01-30 | 2026-01-30 | 445,000 | — | $0 | 445,000 | SEC↗ |
| Slover Peter T | Chief Financial Officer | A Award deriv | 2026-01-30 | 2026-01-30 | 192,000 | — | $0 | 192,000 | SEC↗ |
| Healy John Stephen | General Counsel and Corp Sec | A Award deriv | 2026-01-30 | 2026-01-30 | 206,411 | — | $0 | 206,411 | SEC↗ |
| Watkins Tim | CMO & Head of Development | M Exercise deriv | 2026-01-28 | 2026-01-30 | 3,611 | — | $0 | 252,778 | SEC↗ |
| Watkins Tim | CMO & Head of Development | S Sale | 2026-01-28 | 2026-01-30 | 811 | $14.48 | $11.7K | 0 | SEC↗ |
| Watkins Tim | CMO & Head of Development | M Exercise | 2026-01-28 | 2026-01-30 | 3,611 | $4.50 | $16.2K | 3,611 | SEC↗ |
| Watkins Tim | CMO & Head of Development | S Sale | 2026-01-28 | 2026-01-30 | 2,800 | $14.09 | $39.5K | 811 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-01-05 | 2026-01-06 | 500 | $11.13 | $5.6K | 160,222 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2026-01-05 | 2026-01-06 | 3,670 | $10.35 | $38.0K | 160,722 | SEC↗ |
| Watkins Tim | CMO & Head of Development | M Exercise deriv | 2025-12-29 | 2025-12-30 | 3,611 | — | $0 | 256,389 | SEC↗ |
| Watkins Tim | CMO & Head of Development | M Exercise | 2025-12-29 | 2025-12-30 | 3,611 | $4.50 | $16.2K | 3,611 | SEC↗ |
| Watkins Tim | CMO & Head of Development | S Sale | 2025-12-29 | 2025-12-30 | 3,611 | $12.06 | $43.5K | 0 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2025-12-23 | 2025-12-30 | 4,170 | $12.23 | $51.0K | 164,392 | SEC↗ |
| Miralles Gines Diego | Director | A Award deriv | 2025-06-26 | 2025-06-26 | 14,750 | — | $0 | 14,750 | SEC↗ |
| Ware Olivia C | Director | A Award deriv | 2025-06-26 | 2025-06-26 | 14,750 | — | $0 | 14,750 | SEC↗ |
| Lyons-Williams Lori | Director | A Award deriv | 2025-06-26 | 2025-06-26 | 14,750 | — | $0 | 14,750 | SEC↗ |
| Ignelzi Troy A. | Director | A Award deriv | 2025-06-26 | 2025-06-26 | 14,750 | — | $0 | 14,750 | SEC↗ |
| Brady Todd R. | Director | A Award deriv | 2025-06-26 | 2025-06-26 | 14,750 | — | $0 | 14,750 | SEC↗ |
| Schimmelpennink Evert B. | Director | A Award deriv | 2025-06-26 | 2025-06-26 | 14,750 | — | $0 | 14,750 | SEC↗ |
| Boyce Sarah | Director | A Award deriv | 2025-06-26 | 2025-06-26 | 14,750 | — | $0 | 14,750 | SEC↗ |
| Watkins Tim | CMO & Head of Development | A Award deriv | 2025-04-28 | 2025-04-28 | 260,000 | — | $0 | 260,000 | SEC↗ |
| Watkins Tim | CMO & Head of Development | A Award deriv | 2025-04-28 | 2025-04-28 | 26,000 | — | $0 | 26,000 | SEC↗ |
| Miralles Gines Diego | Director | A Award deriv | 2025-03-14 | 2025-03-17 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Stengone Carmine N. | CEO and President | A Award deriv | 2025-01-31 | 2025-01-31 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | A Award deriv | 2025-01-31 | 2025-01-31 | 110,000 | — | $0 | 110,000 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | A Award deriv | 2025-01-31 | 2025-01-31 | 110,000 | — | $0 | 110,000 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | A Award deriv | 2025-01-31 | 2025-01-31 | 3,700 | — | $0 | 3,700 | SEC↗ |
| Slover Peter T | Chief Financial Officer | A Award deriv | 2025-01-31 | 2025-01-31 | 110,000 | — | $0 | 110,000 | SEC↗ |
| Healy John Stephen | General Counsel and Corp Sec | A Award deriv | 2025-01-31 | 2025-01-31 | 63,589 | — | $0 | 63,589 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2024-11-25 | 2024-11-27 | 1,010 | $16.02 | $16.2K | 168,562 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2024-11-18 | 2024-11-20 | 99 | $17.05 | $1.7K | 169,572 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | S Sale | 2024-11-18 | 2024-11-20 | 6,091 | $16.37 | $99.7K | 169,671 | SEC↗ |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | M Exercise deriv | 2024-08-13 | 2024-08-14 | 12,800 | — | $0 | 161,394 | SEC↗ |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | M Exercise | 2024-08-13 | 2024-08-14 | 12,800 | $1.01 | $12.9K | 12,800 | SEC↗ |
| Boyce Sarah | Director | A Award deriv | 2024-06-24 | 2024-06-24 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Healy John Stephen | General Counsel and Corp Sec | A Award deriv | 2024-06-03 | 2024-06-03 | 160,000 | — | $0 | 160,000 | SEC↗ |
| Schimmelpennink Evert B. | Director | A Award deriv | 2024-05-24 | 2024-05-29 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Brady Todd R. | Director | A Award deriv | 2024-05-24 | 2024-05-29 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Lyons-Williams Lori | Director | A Award deriv | 2024-05-24 | 2024-05-29 | 29,500 | — | $0 | 29,500 | SEC↗ |
| Ware Olivia C | Director | A Award deriv | 2024-05-24 | 2024-05-29 | 3,700 | — | $0 | 3,700 | SEC↗ |
| Ignelzi Troy A. | Director | A Award deriv | 2024-05-24 | 2024-05-29 | 6,350 | — | $0 | 6,350 | SEC↗ |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | A Award deriv | 2024-05-24 | 2024-05-29 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | A Award deriv | 2024-05-24 | 2024-05-29 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Lorrain Daniel S. | Chief Scientific Officer | A Award deriv | 2024-05-24 | 2024-05-29 | 3,700 | — | $0 | 3,700 | SEC↗ |
| Slover Peter T | Chief Financial Officer | A Award deriv | 2024-05-24 | 2024-05-29 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Stengone Carmine N. | CEO and President | A Award deriv | 2024-05-24 | 2024-05-29 | 285,000 | — | $0 | 285,000 | SEC↗ |
| Ignelzi Troy A. | Director | A Award deriv | 2024-05-20 | 2024-05-20 | 23,150 | — | $0 | 23,150 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 455 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 70,498 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 298,975 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 1,931 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 275,769 | — | $0 | 710,494 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 689 | — | $0 | 12,123 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 110,187 | — | $0 | 1,934,776 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 317,988 | — | $0 | 1,741,107 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 434,725 | — | $0 | 434,725 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 2,182 | — | $0 | 11,434 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 348,143 | — | $0 | 1,824,589 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 1,423,119 | — | $0 | 1,423,119 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 9,252 | — | $0 | 9,252 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 1,476,446 | — | $0 | 1,476,446 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 57,565 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 145 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 22,312 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion deriv | 2024-04-09 | 2024-04-11 | 90,747 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion | 2024-04-09 | 2024-04-11 | 2,531 | — | $0 | 2,531 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion | 2024-04-09 | 2024-04-11 | 148,312 | — | $0 | 148,312 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | C Conversion | 2024-04-09 | 2024-04-11 | 391,785 | — | $0 | 391,785 | SEC↗ |